Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368020 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL12994493 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL13227674 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL30433831 | 1.00 | MDM4 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL30434660 | 0.95 | MDM2 (0.52) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL28625947 | 0.95 | MDM2 (0.52) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL28625949 | 0.95 | MDM2 (0.52) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL17991594 | 0.93 | MDM2 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL29401153 | 0.93 | MDM2 (0.54) | MDM4TP53MDM2SIRT2 | |
| SCHEMBL30468161 | 0.93 | SIRT2 (0.55) | MDM4TP53MDM2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361272-A1 | HISTIDINE-BASED UNNATURAL AMINO ACID, ITS PRODUCTION AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-11-27 | — | — | US | claimed |
| CN-120114563-A | Biotin tripeptide with hair growth function and composition, preparation method and application thereof | 天津科技大学 | 2025-06-10 | — | — | CN | claimed |
| CN-119661691-A | N-terminal modified cosmetic polypeptide composition and synthesis method thereof | 湖南益安生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119661633-A | Method for full liquid phase synthesis of blue copper peptide | 湖南益安生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119638822-A | Full liquid phase synthesis method of oligopeptide-1 | 湖南益安生物科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-118994321-B | Preparation method and application of cosmetic cyclic peptide reagent | 杭州皓阳生物技术有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-118948698-B | Refreshing oil control composition and preparation process thereof | 广州市可颜化妆品有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-114249810-B | Synthetic method of somalupeptide | 深圳翰宇药业股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119306796-A | Golden-silk-flos chrysanthemi oligopeptide and 9 peptide with blood fat reducing and weight losing effects, and preparation methods and applications thereof | 天津科技大学 | 2025-01-14 | — | — | CN | claimed |
| CN-118994321-A | Preparation method and application of cosmetic cyclic peptide reagent | 杭州皓阳生物技术有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-114487164-A | Separation detection method for protected amino acid and impurity with N-terminal removed protecting group | 四川汇宇制药股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114014912-B | Method for preparing leuprorelin by combining solid phase and liquid phase | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-113121673-B | Method for preparing elcatonin by solid-liquid combination method | 润辉生物技术（威海）有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114249810-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114249808-A | Synthesis method of Cagrilintide | 杭州诺泰澳赛诺医药技术开发有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-114057862-A | Synthetic method of GLP-1(1-37) polypeptide | 安徽省国平药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-113880921-B | Synthetic method of bremer langdan acetate | 浙江湃肽生物有限公司南京分公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114014912-A | Method for preparing leuprorelin by combining solid phase and liquid phase | 浙江湃肽生物有限公司南京分公司 | 2022-02-08 | — | — | CN | claimed |
| CN-113402465-A | Preparation method of N-9-fluorenylmethoxycarbonyl-N' -trityl-L-histidine | 常州吉恩药业有限公司 | 2021-09-17 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361272-A1 | HISTIDINE-BASED UNNATURAL AMINO ACID, ITS PRODUCTION AND USE | H1-0, BCAT1, H1-2 | MDM4 1798/4885TP53 2290/4885MDM2 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.